USP7–PKM2-Mediated Metabolic Reprogramming in Macrophage Polarization During Acute Pancreatitis

Study Background and Research Question

Severe acute pancreatitis (SAP) is a life-threatening inflammatory disorder characterized by rapid progression, high morbidity, and significant risk of multi-organ failure. Despite advancements in supportive care, there are no approved therapeutic agents that effectively alter SAP's clinical course. Recent research attention has focused on the role of innate immune cells—particularly macrophages—in driving both the onset and resolution of pancreatic inflammation. Within this context, the polarization of macrophages into pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes is recognized as a pivotal determinant of disease severity. However, the molecular mechanisms governing this polarization, and the potential metabolic checkpoints involved, remain incompletely understood (paper). This study investigates whether the deubiquitinase ubiquitin-specific protease 7 (USP7) regulates macrophage phenotype switching in SAP, and if so, how this relates to the metabolic enzyme pyruvate kinase M2 (PKM2), a known mediator of glycolytic flux and immune cell fate.

Key Innovation from the Reference Study

The principal innovation of Yao Wu et al.'s work lies in delineating a direct mechanistic link between USP7 activity and PKM2 function in macrophage polarization during SAP. The authors demonstrate that USP7 governs the deubiquitination, phosphorylation, and nuclear translocation of PKM2, thereby modulating the metabolic reprogramming essential for the M1 macrophage phenotype. This molecular axis provides a new conceptual framework for targeting immunometabolism in severe inflammatory diseases (paper).

Methods and Experimental Design Insights

The study employed a multifaceted experimental approach integrating in vivo and in vitro models:

• Expression analysis of USP7 in pancreatic tissues of SAP mice using histology and immunofluorescence.
• Macrophage phenotyping and inflammatory marker assessment via flow cytometry and Western blotting.
• Seahorse extracellular flux analysis to quantify glycolytic (ECAR) and oxidative (OCR) metabolism in macrophage populations.
• Co-immunoprecipitation and ubiquitinated-IP assays to determine the interaction and post-translational modification status of PKM2.
• Pharmacological intervention using a selective PKM2 inhibitor to test the dependency of USP7-mediated effects on PKM2 activity.

This design allowed for dissection of both the phenotypic and metabolic consequences of USP7 manipulation, and for direct testing of the causal role of PKM2 in mediating macrophage functional outcomes.

Core Findings and Why They Matter

Key findings from the study can be summarized as follows:

• USP7 is upregulated in SAP-associated macrophages, and its knockdown ameliorates disease severity, as evidenced by reductions in serum amylase, lipase, and pro-inflammatory cytokines (paper).
• Macrophage polarization is shifted from M1 to M2 by USP7 knockdown, both in vivo and in vitro, establishing USP7 as a driver of pro-inflammatory macrophage programming.
• Metabolic reprogramming underlies this phenotype switch. USP7 knockdown decreases glycolysis (lower ECAR) and enhances oxidative phosphorylation (higher OCR), consistent with the metabolic profile of M2, anti-inflammatory macrophages.
• USP7 directly modulates PKM2 post-translational state by promoting deubiquitination and phosphorylation, facilitating PKM2 nuclear translocation, a process known to promote glycolytic gene expression and M1 polarization.
• Pharmacological inhibition of PKM2 partially reverses the protective effects of USP7 knockdown, confirming that PKM2 is a downstream effector of USP7 in this context. This finding substantiates the concept that targeting metabolic checkpoints can modulate immune phenotypes in inflammatory disease (paper).

These findings matter because they position the USP7–PKM2 axis as a potential therapeutic target for modulating innate immunity in SAP, with broader implications for other macrophage-driven inflammatory disorders.

Comparison with Existing Internal Articles

Recent internal articles have highlighted the translational potential of PKM2 inhibition in oncology and immunometabolism research:

• PKM2 Inhibitor (Compound 3k): Unraveling the Intersection... explores how selective PKM2 inhibition affects both cancer cell metabolism and immune regulation, echoing the reference study's focus on immunometabolic reprogramming.
• PKM2 Inhibition as a Cornerstone Strategy: Mechanistic In... provides mechanistic context for PKM2's role in immune cell polarization, complementing the new evidence that inhibition of PKM2 can modulate macrophage phenotype in non-cancer settings.
• PKM2 inhibitor (compound 3k): Precision Disruption of Can... discusses the selective and potent disruption of glycolytic metabolism in both tumor and immune cells, supporting the rationale for repurposing such inhibitors in inflammation models.

The current reference paper advances this field by showing, in a disease-specific context (SAP), that the USP7–PKM2 axis is not merely correlative but functionally determinant for macrophage-driven pathology.

Limitations and Transferability

While the study provides compelling mechanistic insight, several limitations must be considered:

• Translational uncertainty: The findings are based on murine models of SAP and primary macrophage cultures; the applicability to human disease remains to be determined (paper).
• Pharmacological specificity: Although a selective PKM2 inhibitor was used, off-target effects cannot be fully excluded, and the precise translational window for metabolic intervention in acute inflammation is not yet defined.
• Temporal dynamics: The role of USP7–PKM2 signaling at different stages of SAP progression (early vs. late inflammation) was not dissected in detail.

Overall, while the USP7–PKM2 axis is a promising target, further studies in human tissues and disease models are needed to validate therapeutic implications.

Protocol Parameters

• Immunofluorescence for USP7/PKM2 | 1:100 antibody dilution | Formalin-fixed mouse pancreas | Enables spatial mapping of USP7/PKM2 expression | paper
• Flow cytometry for macrophage phenotyping | 1 × 10⁶ cells/sample | Mouse peritoneal or pancreatic cell suspensions | Quantifies M1/M2 populations | paper
• Seahorse metabolic flux analysis | 1 × 10⁵ cells/well | Primary macrophage cultures | Measures ECAR/OCR metabolic profiles | paper
• PKM2 inhibitor (compound 3k) administration | 5 mg/kg, oral, every 2 days | In vivo SAP mouse model | Tests metabolic dependency of immune phenotypes | product_spec
• In vitro PKM2 inhibition | 0.18–1.56 μM (cell lines) | Cancer and immune cells | Inhibits PKM2-dependent glycolysis and polarization | product_spec

Research Support Resources

Researchers aiming to explore the immunometabolic regulation highlighted in this study can utilize PKM2 inhibitor (compound 3k) (SKU B8217) as a validated, selective small-molecule tool for targeting PKM2 in both tumor and inflammatory models (source: product_spec). This compound has demonstrated potency in disrupting aerobic glycolysis and modulating immune cell fate in preclinical settings, supporting workflows that interrogate the metabolic basis of macrophage polarization and disease progression. For protocol guidance and advanced workflow recommendations, relevant internal articles and product documentation provide further technical detail.